Back in October 2013, Merck & Co. Inc. chairman and CEO Kenneth C. Frazier announced a major strategic restructuring to create “greater efficiencies” for the company. The goal: to put its R&D operations in order and pare its annual operating expenses by approximately $2.5 billion by the end of 2015.